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The discovery of the highly potent antibiotic teixobactin, which kills the bacteria without any detectable 
resistance, has stimulated interest in its structure activity relationship. However, a molecular structure-
activity relationship has not been established so far for teixobactin. Moreover, the importance of the 
individual amino acids in terms of their L/D configuration and their contribution to molecular structure and 
biological activity are still unknown. For the first time, we have defined the molecular structure of seven 
teixobactin analogues through the variation of the D/L configuration of its key residues, namely N-Me-D-Phe, 
D-Gln, D-allo-Ile and D-Thr. Furthermore, we have established the role of the individual D amino acids and 
correlated this to the molecular structure and biological activity. Through extensive NMR and structural 
calculations, including molecular dynamics simulations we have revealed the residues for maintaining a 
reasonably unstructured teixobactin which is imperative for biological activity. 
The discovery of the highly potent antibiotic teixobactin1 to 
cope with the growing problem of antimicrobial resistance 
(AMR)2 has provided a much needed impetus to antibiotic 
research. Although teixobactin does not mitigate all problems 
related to antibiotic resistance, it is a definite step in the right 
direction. In the short time since the antibiotic was discovered, 
several research groups, including our own, have made 
noteworthy contributions in the areas of total synthesis,3, 4 
syntheses and biological activities of teixobactin analogues5, 6, 
7, 8 and understanding the mechanisms of teixobactin.9, 10, 11 
 
Replacing the enduracididine amino acid with its structurally closest 
natural amino acid arginine leads to Arg10 teixobactin analogue. The 
Arg10 teixobactin analogue follows a similar antibacterial activity 
trend as teixobactin (Figure 1). 3, 5, 6, 7 Therefore, conclusions drawn 
by synthesising analogues of the Arg10 teixobactin derivative 
should hold true for teixobactin as well.  
Teixobactin is a cyclic depsipeptide and contains 11 amino 
acids, out of which 4 are D amino acids, namely N-Me-D-Phe, 
D-Gln, D-allo-Ile and D-Thr (Figure 1, marked in red). Peptides 
containing more D amino acids are generally less susceptible 
to enzymatic degradation12 which may well be applicable for 
teixobactin.1 In our previous work6 we had already established 
the importance of the D-amino acids through the total 
synthesis of both D and L analogues of teixobactin. Replacing 
the D amino acids with their corresponding L configurations 
(except D-Thr8) results in a 64-times decrease in antibacterial 
activity against S. aureus. The minimum pharmacophore of 
teixobactin, lipobactin7 had also been published by Yang et al. 
indicating that residues 1-5 were probably responsible for 
membrane anchoring. It had also been shown that D-Thr8 is 
critical for antibacterial activity and modification of the 
configuration of any residues in the core ring structure of 
teixobactin results in a significant decrease in activity.  
 
In an interesting work, Yang et al, had showed that the 
complete enantiomeric teixobactin maintains full anti-bacterial 
activity (except in Staphylococcus epidermis, where it was 
reduced) indicating the possibility that only the relative 
configurations of amino acids and not their absolute 
configurations were important for antibacterial activity.   
 
It is not yet known, however, if a molecular structure (three- 
dimensional structure)-activity relationship exists for 
teixobactin. To date, with the exception of the structural 
deduction of teixobactin published by Ling et. al.,1 no 
molecular structural studies on teixobactin or its analogues 
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have been reported. Moreover, the impact on the molecular structure and
Figure 1. Structure of (A) Teixobactin and (B) Teixobactin-Arg10 with the D amino acids highlighted in red and the structural differences marked in blue. 
Figure 2. A. Structure of teixobactin analogue 1 (DDDD) exhibiting native 
stereochemistry. B. Structure of analogue 2 (LLLL) containing L-Thr8. Overlays of 
the 20 lowest energy structures aligned to the backbone atoms of the cyclic 
region are displayed. Atoms are colored according to their RMSD, fading to white 
at higher RMSD. Atom transparency also increases with RMSD, with more highly 
disordered regions fading to invisibility. For clarity, only backbone atoms and the 
non-hydrogen atoms of Arg10 are displayed.  
activity of teixobactin by varying individual amino acids in 
terms of their L/D configuration is still unknown.  This study 
aims to explain why L analogues of teixobactin are not active. 
We have selected the D amino acid residues and systematically 
replaced them with L configurations to understand the 
minimum number of D amino acid residues required to 
maintain biological activity. Furthermore, the low cost of L 
amino acids was expected to lower the financial constraint on 
teixobactin development. For the first time, we have 
determined molecular structures of seven teixobactin 
derivatives by changing D/L configurations from NMR, their 
antibacterial activity and lipid II binding. The results from our 
work will enable the better understanding of molecular 
structure activity relationship of teixobactins and their further 
development as drug like molecules. 
 
In this work, we have investigated the role of each of the D 
amino acids, their impact on the molecular structure and 
activity of teixobactin and whether there exists a structure-
activity relationship for the molecule. Through the syntheses 
of seven analogues of Arg10-teixobactin (Table 1), followed by 
extensive NMR and structural calculations we have shown the 





Code Configuration of Amino Acids 
  N-Me-Phe Gln Ile Thr MIC† 
1 DDDD D D D D 2 
2 LLLL L L L L GAW‡ 
3 DDLD D D L D GAW 
4 DLDD D L D D GAW 
5 LDDD L D D D 32-64 
6 LLDD L L D D GAW 
7 LLLD* L L L D 128 
Table 1. List of analogues of Arg10-teixobactin synthesized by varying the D/L 
configuration of the key residues N-Me-D-Phe1, D-Gln4, D-allo-Ile5 and D-Thr8. 
† MIC values were measured against S. aureus and are given in µg/mL 
‡ Growth in all wells. 
*This analogue contains an acetylated Phe instead of an N-Me-Phe residue. 
Our initial efforts were focused towards understanding the 
pivotal role played by the stereochemistry of D-Thr8 upon the 
gross structure of teixobactin. This was achieved through the 
synthesis of analogue 2 (LLLL) and subsequent comparison 
with analogue 1 (DDDD, Figure 2). Outside the cyclic region 
encompassing residues 8 to 11 the peptide was largely 
unstructured (Figure 2A).  The altered topological environment 
available to the analogue 2 (LLLL) makes it energetically 
favourable to adopt a well-defined hairpin structure (figure 
2B). 
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Figure 3. Effect of stereochemistry at different positions on the structure of teixobactin analogues. A. Majority of variation observed in structural ensembles 
accounted for by varying levels of disorder in the N-terminal residues. Positions labelled in black type have had their stereochemistry altered. The name of the 
analogues is as described in Table 1. B-F. Backbone traces of 20 lowest energy structures aligned to the backbone atoms of the cyclic reg ion. Atom color and 
transparency as in Figure 1. 
The teixobactin analogues routinely gave spectra of the 
highest quality (Figure S16), which made complete atomic 
assignment of each analogue possible (Table S2). Subsequent 
measurement of dipolar correlations allowed for full structural 
characterisation. The number of visible NOE cross-peaks 
(Figure S16) varied with different analogues: those with D-Gln4 
(for example figure S16 red contours) contained very few 
medium- and long-range correlations, which is typical for 
highly dynamic, unstructured peptides in which nuclei are 
seldom in close enough proximity for NOE build-up to occur. 
This flexibility is reflected in their high RMSD (Figure 2 A, 
Figure 3, Table S3). 
   
In contrast, analogues possessing L-Gln4 (2, 4, 6, 7) (for 
example figure S16 blue contours) contained many more 
crosspeaks in their NOESY spectra, some of which are 
categorised as long-range (Table 2), a category entirely missing 
from the D-Gln4 containing analogues (1, 3, 5). Having 
numerous medium- to long-range NOEs is characteristic of 
peptides adopting a higher degree of structure, and this 
situation is reflected in their sub- to low Angstrom 
convergence (Figure 2 B, Table S3). 
 
Possessing an L-Ile5 imparts a slight tendency for structure on 
the teixobactin analogues (Figure 3 A, B, F) but does not result 
in a high deviation from the original structure unlike that 
observed for L-Gln4. For instance, the RMSD of analogue 1 
(native stereochemistry) is ~3 Å (Figure 2 A, Figure 3 A) 
whereas that of 3 (DDLD), in which D-allo-Ile5 has been 
replaced by L-Ile5, is reduced to ~2 Å (Table 2, Figure 3 A, B). A 
similar slight reduction in RMSD is observed in 7 (LLLD, 0.93 Å; 
Table 2, Figure 3 A, F) when compared to 6 (LLDD, 1.06 Å; 
Table 2, Figure 3 A, E) where again, the only difference 
between them is the stereochemistry at position 5. The 
stereochemistry of position 1 has little to no effect on overall 
structure, as can be seen when one compares the RMSDs of 1 
(DDDD) to 5 (LDDD, both ~3 Å; Figure 2A, Figure 3 A, D, Table 
S3). Although highly disordered, the N-terminal domains of 
both these analogues occupy a similar overall spatial region. 
Since the stereochemistry of position 1 is not important to the 
structure, it is likely that D configuration is important for 
slowing down enzyme degradation or for biological activity. 
 
Taken together, this data allows us to conclude that the 
stereochemistry of position 4 is critical to structural stability. 
An ubiquitous structural characteristic of the L-Gln4 containing 
analogues absent from the D-Gln4 containing analogues is that 
Ile6 packs against Ile11. It is therefore possible that this long-
range packing arrangement is made possible by the altered 
stereochemistry at position 4 and has the effect of stabilising 
the structures. We analysed the nature of this packing through 
extended molecular dynamics (MD) simulations on the 
microsecond time-scale. Trajectories were calculated for a 
total of 0.1 μs for analogue 1 and 7 in explicit solvent (Figure 
S17). It was immediately obvious from the simulations that the 
native analogue seldom visits this packing arrangement (Figure 
S17 B), and on the few occasions it does it is very short-lived.  
However, the sidechains of Ile6 and Ile11 remain in constant 
hydrophobic contact throughout the entire simulation in the 
case of 7 (LLLD, Figure S17 B). 
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Functionally, it was important to understand how this 
increased stability through packing might explain the MICs 
observed in all analogues except 5 (LDDD, Table 1). A plausible 
mechanism was also revealed through MD, in that the 
sidechain of Arg10 is less solvent exposed in 7 (LLLD, Figure S17 
A). This interaction is stabilised through the formation of 
numerous transient intramolecular hydrogen bonds between 
Arg10 and other residues (Figure S17, bottom panel), a 
situation almost entirely lacking in the native analogue. 
 
Therefore, it is possible to surmise that if the hydrogen bond 
donors of the guanidine group of Arg10 are spending a 
considerable proportion of their time in forming intra-
molecular hydrogen bonds then they are unavailable for the 
formation of inter-molecular bonds. Thus, if Arg10 is 
unavailable for involvement in intermolecular recognition 
events, this could help to explain the decrease in MIC in case 
of analogue 7 (LLLD) as compared to 1 (DDDD, Table 1). The 
frequency of unfavoured backbone torsion angles present in 
the teixobactin analogues (Table S3) correlates strongly with D 
amino acid content. This could be due to limitations with the 
analysis algorithms used. 
 
Figure S17 reveals that native teixobactin (Arg10) is highly 
dynamic in solution, whereas an analogue containing L-Gln4 is 
both more tightly packed and structurally stable. This 
increased burial (figure S17 A) is probably a result of the 
formation of a number of transient hydrogen bonds between 
the guanidine group of Arg10 and other polar sidechains in the 
analogue (teal bars). In contrast, Arg10 only forms two short-
lived hydrogen bonds (red bars) throughout the whole 
simulation in the native form. 
 
Complex formation of teixobactin analogues 1 (DDDD) and 2 
(LLLL) with lipid II and geranyl pyrophosphate were performed 
as described previously using TLC (SI VIII) 1. Both analogues 
bind to lipid II and geranyl pyrophosphate which is indicated 
by the reduction of lipid II/ geranyl pyrophosphate visible on 
TLC (figure S18 & S19). The binding of lipid II to LLLL analogue 
is unexpected as the LLLL is not biologically active. Therefore, it 
can be concluded that the binding assay on isolated lipid II 
does not necessarily reflect whole cell activities. A plausible 
explanation for this can be that lipid II is more freely available 
in solution than in the case of bacteria. 
 
We have for the first time determined the 3D molecular 
structure of seven teixobactin analogues and established the 
importance of the individual amino acids in terms of their D/L 
configurations in maintaining a relatively unstructured 
teixobactin. Furthermore, we can directly correlate this 
propensity for structure with antimicrobial activity and have 
identified a possible mechanism by which this disorder is 
maintained. We have shown that the D- N-Me-Phe11 is not 
important from a structural standpoint. On the other hand, we 
have identified D-Gln4 as being very essential and D-Ile5 being 
important in maintaining the disordered structure of 
teixobactin, which is vital for its biological activity. We believe 
this work to be critical in understanding the structural-activity 
relationship and mechanism of teixobactin and its analogues 
and their further development as drug like molecules. The 
results presented in this work are of broad general interest 
and are expected to facilitate the future development of 
teixobactin derivatives and peptide based antibiotics for 
addressing the serious challenges posed by AMR. 
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